Strongyloides seroprevalence before and after an ivermectin mass drug administration in a remote Australian Aboriginal community
Therese M Kearns, Bart J Currie, Allen C Cheng, James McCarthy, Jonathan R Carapetis, Deborah C Holt, Wendy Page, Jennifer Shield, Roslyn Gundjirryirr, Eddie Mulholland, Linda Ward, Ross M Andrews
PLOS NEGLECTED TROPICAL DISEASES | PUBLIC LIBRARY SCIENCE | Published : 2017
BACKGROUND: Strongyloides seroprevalence is hyper-endemic in many Australian Aboriginal and Torres Strait Islander communities, ranging from 35-60%. We report the impact on Strongyloides seroprevalence after two oral ivermectin mass drug administrations (MDAs) delivered 12 months apart in a remote Australian Aboriginal community. METHODS: Utilizing a before and after study design, we measured Strongyloides seroprevalence through population census with sequential MDAs at baseline and month 12. Surveys at months 6 and 18 determined changes in serostatus. Serodiagnosis was undertaken by ELISA that used sonicated Strongyloides ratti antigen to detect anti-Strongyloides IgG. Non-pregnant particip..View full abstract
Awarded by National Health and Medical Research Council
Awarded by Cooperative Research Centre for Aboriginal Health
Awarded by Northern Territory Research Innovation Board and Fund (NTRIB)
The project was funded by National Health and Medical Research Council (NHMRC 605804). The following authors were investigators on the grant application - TMK, BJC, ACC, JM, JRC, DCH, WP, EM, RMA. Funding was also obtained from the Cooperative Research Centre for Aboriginal Health (CRCAH HS 331) by TMK, RMA and the Northern Territory Research Innovation Board and Fund (NTRIB Grant Round 6 - 2008) by TMK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.